Fredun Pharmaceuticals reports 87% revenue rise and 94% net profit growth in H1 FY27
Fredun Pharmaceuticals · Pharmaceuticals & Biotechnology
Key highlights
- H1 FY27 total income ₹495.88 Cr vs ₹265.15 Cr in H1 FY26, up 87.02%; EBITDA ₹75.38 Cr vs ₹39.33 Cr, up 91.67%; PAT ₹31.99 Cr vs ₹16.50 Cr, up 93.92%
- Fredun acquired 26% stake in Goodman Vetcare at ₹300 Cr valuation in September 2026; Goodman plans 8+ new stores and targeting ₹100 Cr revenue by FY31
- Fredun acquired pet-wellness brand Furlicks from USV and Wellbeing Nutrition; plans to expand products from 6 to 22 SKUs over 6–9 months; launched PAWTALKS pet healthcare platform on Sep 4, 2026
Why it's rated major development: the year-on-year change is 93% (50% or more)
Figures checked against the filing by a second AI read. About the business, not the share price.
Original filing
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Read the filing on BSE (PDF) →Companies guiding to strong growth
Ranked by management's own guidance on revenue and margins — not by us.
Aerospace & Defense
Sign up free to see all 6 →
See full rankingsRank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
More from Fredun Pharmaceuticals
- Financial resultsNotableFredun Pharmaceuticals Limited announces Q2 & H1 FY2026 unaudited results and NSE listing plan
- Acquisition / mergerNotableFredun Pharmaceuticals Ltd. acquires pet-wellness brand Furlicks from USV & Wellbeing Nutrition
Other acquisition / merger filings this fortnight
- IndiGrid Infrastructure Trust Q2 FY27 Earnings Conference Call Transcript Released
- Cubical Financial Services Ltd announces promoter reclassification post open offer
- Novus Loyalty Limited approves acquisition of AutoPe Payment Solutions via share swap
- Shish Industries Limited files Composite Scheme of Amalgamation proposal
- Jubilant Ingrevia Limited updates on acquisition of 40% stake in Zettaone Technologies
- NHC Foods approves quarter results, 99.98% Sachmaas Foods investment, two appointments
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Summary written by Arthneeti from the company's filing with the stock exchange; check the original filing for full details. Arthneeti is a research and analytics platform, not a SEBI-registered investment adviser, and nothing here is a recommendation to buy or sell.